STOK May 2024 2.500 call
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | 2.0500 |
| Ask | 4.9000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 2.5000 - 2.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksStoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireStoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BEDFORD, Mass., May 06, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause
ZacksEarnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
